texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x
Request an Appointment

Dallas Clinical Trials

Texas Oncology cancer centers in Dallas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Dallas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current clinical trials.

Our cancer researchers in the Dallas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in a Clinical Trial

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Dallas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Dallas area and talk to your doctor to determine which clinical trial is right for you.

ALL / MDS

Title: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)

Indication: ALL / MDS

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

AML

Title: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Indication: AML

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Anal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Plano West

Phase: I

Any Childhood Cancer

Title: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Project: Every Child for Younger Patients With Cancer

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Biliary Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Allen

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Denton

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Allen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Denton

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-McKinney

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: IV

Bladder Cancer

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph3 Dura Trem EV MIBC Ca View

Description: D910PC00001: A Phase III Randomized Open-Label Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Dura Trem EV MIBC Ca View

Description: D910PC00001: A Phase III Randomized Open-Label Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Dura Trem EV MIBC Ca View

Description: D910PC00001: A Phase III Randomized Open-Label Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Dura Trem EV MIBC Ca View

Description: D910PC00001: A Phase III Randomized Open-Label Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Indication: Bladder Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Bladder Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Plano West

Phase: IV

Blood Cancer

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Brain Cancer

Title: Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Indication: Brain Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Indication: Brain Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Indication: Brain Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Indication: Brain Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

Indication: Brain Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Breast Cancer

Title: Perimeter RCT Study: A randomized, controlled, open-label, multi-center trial to determine if the adjuive use of OTIS (optical tissue imaging system) will significantly reduce the proportion of subjects with at least one final pathologic positive margin in breast conservation surgery

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Title: Perimeter RCT Study: A randomized, controlled, open-label, multi-center trial to determine if the adjuive use of OTIS (optical tissue imaging system) will significantly reduce the proportion of subjects with at least one final pathologic positive margin in breast conservation surgery

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Title: Perimeter RCT Study: A randomized, controlled, open-label, multi-center trial to determine if the adjuive use of OTIS (optical tissue imaging system) will significantly reduce the proportion of subjects with at least one final pathologic positive margin in breast conservation surgery

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: PH1b/2 Durva+Pacl mTNBC(Begonia) View

Description: A Phase IB/II 2-Stage Open-label Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: PH1b/2 Durva+Pacl mTNBC(Begonia) View

Description: A Phase IB/II 2-Stage Open-label Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: PH1b/2 Durva+Pacl mTNBC(Begonia) View

Description: A Phase IB/II 2-Stage Open-label Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: PH1b/2 Durva+Pacl mTNBC(Begonia) View

Description: A Phase IB/II 2-Stage Open-label Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: PH1b/2 Durva+Pacl mTNBC(Begonia) View

Description: A Phase IB/II 2-Stage Open-label Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: PH1b/2 Durva+Pacl mTNBC(Begonia) View

Description: A Phase IB/II 2-Stage Open-label Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 HER2+/ER+ BC View

Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 Sac Gov Pemb vs PC BC (ASCENT-04) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Sac Gov Pemb vs PC BC (ASCENT-04) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Sac Gov Pemb vs PC BC (ASCENT-04) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Sac Gov Pemb vs PC BC (ASCENT-04) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Sac Gov Pemb vs PC BC (ASCENT-04) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Sac GOv vs PC BC (ASCENT-03) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Sac GOv vs PC BC (ASCENT-03) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Sac GOv vs PC BC (ASCENT-03) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Sac GOv vs PC BC (ASCENT-03) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Sac GOv vs PC BC (ASCENT-03) View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: SCRI:BRE 405: Ph3 AZD9833 vs AI or Tamox HR+/HER2- BC (CAMBRIA-1) View

Description: CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive LocoregionalTherapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (D8531C00002)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph1/2 FIH NUV-868 Olap or Enzal Select Solids View

Description: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH NUV-868 Olap or Enzal Select Solids View

Description: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH NUV-868 Olap or Enzal Select Solids View

Description: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH NUV-868 Olap or Enzal Select Solids View

Description: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: IV

Carcinoid

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Allen

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Denton

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-McKinney

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Plano East

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Plano West

Phase: II

Cervical Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Plano West

Phase: IV

Colon Cancer

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Allen

Phase: III

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph2 Boten(Agen1181) Agen2034 CRC without Liver Mets View

Description: A RANDOMIZED OPEN LABEL PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) OR INVESTIGATOR'S CHOICE STANDARD OF CARE (REGORAFENIB OR TRIFLURIDINE AND TIPIRACIL) FOR THE TREATMENT OF REFRACTORY METASTATIC COLORECTAL CANCER(C-800-25)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Boten(Agen1181) Agen2034 CRC without Liver Mets View

Description: A RANDOMIZED OPEN LABEL PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) OR INVESTIGATOR'S CHOICE STANDARD OF CARE (REGORAFENIB OR TRIFLURIDINE AND TIPIRACIL) FOR THE TREATMENT OF REFRACTORY METASTATIC COLORECTAL CANCER(C-800-25)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Boten(Agen1181) Agen2034 CRC without Liver Mets View

Description: A RANDOMIZED OPEN LABEL PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) OR INVESTIGATOR'S CHOICE STANDARD OF CARE (REGORAFENIB OR TRIFLURIDINE AND TIPIRACIL) FOR THE TREATMENT OF REFRACTORY METASTATIC COLORECTAL CANCER(C-800-25)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Boten(Agen1181) Agen2034 CRC without Liver Mets View

Description: A RANDOMIZED OPEN LABEL PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) OR INVESTIGATOR'S CHOICE STANDARD OF CARE (REGORAFENIB OR TRIFLURIDINE AND TIPIRACIL) FOR THE TREATMENT OF REFRACTORY METASTATIC COLORECTAL CANCER(C-800-25)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX View

Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX View

Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX View

Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX View

Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Plano West

Phase: IV

Colorectal Cancer

Title: A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)

Indication: Colorectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)

Indication: Colorectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)

Indication: Colorectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)

Indication: Colorectal Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Endometrial Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano West

Phase: IV

Title: Ph1/2a Narazaciclib + Letrozole 2nd or 3rd LOT Endometrial View

Description: A Multi-center Phase 1/2a Study of Narazaciclib (ON 123300) in Combination with Letrozole as Second- or Third-line Therapy for the Treatment of Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer (19-02)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2a Narazaciclib + Letrozole 2nd or 3rd LOT Endometrial View

Description: A Multi-center Phase 1/2a Study of Narazaciclib (ON 123300) in Combination with Letrozole as Second- or Third-line Therapy for the Treatment of Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer (19-02)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2a Narazaciclib + Letrozole 2nd or 3rd LOT Endometrial View

Description: A Multi-center Phase 1/2a Study of Narazaciclib (ON 123300) in Combination with Letrozole as Second- or Third-line Therapy for the Treatment of Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer (19-02)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2a Narazaciclib + Letrozole 2nd or 3rd LOT Endometrial View

Description: A Multi-center Phase 1/2a Study of Narazaciclib (ON 123300) in Combination with Letrozole as Second- or Third-line Therapy for the Treatment of Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer (19-02)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Esophageal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Esophageal Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Plano West

Phase: IV

Ewing's Sarcoma

Title: Vigil & Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)

Indication: Ewing's Sarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Fallopian Tube Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Allen

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Denton

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Gall Bladder Cancer

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Plano West

Phase: IV

Gastric Cancer

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Plano West

Phase: IV

Germ Cell Tumor

Title: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Indication: Germ Cell Tumor

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Germ Cell Tumors

Title: Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Indication: Germ Cell Tumors

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Phase 3 Accelerated BEP Trial: A Ramdomized Phase 3 Trial of Accelerated vs. Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Indication: Germ Cell Tumors

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Glioma

Title: A Phase 2 Study of Dabrafenib (NSC# 763760, IND# TBD) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) 

Indication: Glioma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) 

Indication: Glioma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: I & II

Graft-Versus-Host-Disease

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft-Versus-Host-Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft-Versus-Host-Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft-Versus-Host-Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft-Versus-Host-Disease

Location: Texas Oncology-Waxahachie

Title: Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

Indication: Graft-Versus-Host-Disease

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Head and Neck

Title: A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK - RDOTAP/HPV-16 E6 & E7 Pep-tides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Sub-jects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection

Indication: Head and Neck

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK - RDOTAP/HPV-16 E6 & E7 Pep-tides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Sub-jects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection

Indication: Head and Neck

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK - RDOTAP/HPV-16 E6 & E7 Pep-tides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Sub-jects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection

Indication: Head and Neck

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK - RDOTAP/HPV-16 E6 & E7 Pep-tides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Sub-jects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection

Indication: Head and Neck

Location: Texas Oncology-Waxahachie

Phase: II

Head and Neck Cancer

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: IV

Hematologic

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Waxahachie

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Plano East

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Plano West

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Plano West

Phase: IV

Hematologic Malignancy

Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3?) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors.

Indication: Hematologic Malignancy

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3?) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors.

Indication: Hematologic Malignancy

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3?) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors.

Indication: Hematologic Malignancy

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3?) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors.

Indication: Hematologic Malignancy

Location: Texas Oncology-Waxahachie

Phase: I/II

High Risk Rhabdomyosarcoma 

Title: A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)

Indication: High Risk Rhabdomyosarcoma 

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Idiopathic Thrombocytopenia

Title: Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim

Indication: Idiopathic Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim

Indication: Idiopathic Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim

Indication: Idiopathic Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim

Indication: Idiopathic Thrombocytopenia

Location: Texas Oncology-Waxahachie

Phase: IV

Kidney Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Plano West

Phase: I

Leukemia

Title: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogenic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(VIALE-T)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Allen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Denton

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-McKinney

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Plano East

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase View

Description: A phase IIIb multi-center open-label randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12302)

Indication: Leukemia

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase View

Description: A phase IIIb multi-center open-label randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12302)

Indication: Leukemia

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Plano West

Phase: IV

Liver Cancer

Title: Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Indication: Liver Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II & III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Plano West

Phase: IV

Low-Grade Glioma 

Title: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Indication: Low-Grade Glioma 

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Lung Cancer

Title: A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Parcipants with Newly Diagnosed Untreated Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Parcipants with Newly Diagnosed Untreated Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Parcipants with Newly Diagnosed Untreated Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Parcipants with Newly Diagnosed Untreated Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: PLT

Title: EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: PLT

Title: EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: PLT

Title: EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: PLT

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph II/III Raptor trial View

Description: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II/III

Title: Ph II/III Raptor trial View

Description: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II/III

Title: Ph II/III Raptor trial View

Description: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: II/III

Title: Ph II/III Raptor trial View

Description: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II/III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor View

Description: A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC View

Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: IV

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Lymphoma

Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: Ib

Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: Ib

Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: Ib

Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Indication: Lymphoma

Location: Texas Oncology-Waxahachie

Phase: Ib

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Waxahachie

Title: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Lymphomas

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Allen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Denton

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-McKinney

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Plano West

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: I

Title: LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: II/III

Title: LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: II/III

Title: LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II/III

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-McKinney

Phase: III

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: II

Melanoma

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Plano West

Phase: IV

Miscellaneous

Title: Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up (PRO-0425)

Indication: Miscellaneous

Location: Texas Center for Proton Therapy

Title: An Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL)

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: An Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL)

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: An Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL)

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: An Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL)

Indication: Miscellaneous

Location: Texas Oncology-Waxahachie

Title: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Indication: Miscellaneous

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Indication: Miscellaneous

Location: Texas Oncology-Waxahachie

Phase: III

Myelodysplastic Syndrome

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Plano West

Phase: IV

Myelofibrosis

Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Waxahachie

Myelomas

Title: Ph1 Dara r/r MM View

Description: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (FT576-101)

Indication: Myelomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: Ph1 Dara r/r MM View

Description: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (FT576-101)

Indication: Myelomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: Ph1 Dara r/r MM View

Description: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (FT576-101)

Indication: Myelomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Allen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Waxahachie

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-McKinney

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Plano East

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Plano West

Phase: IV

Neuroblastoma

Title: A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Indication: Neuroblastoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Indication: Neuroblastoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Indication: Neuroblastoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Neuroblastoma

Title: A Phase 2 Randomized Study of Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Indication: Neuroblastoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma

Indication: Neuroblastoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Neuroendocrine Tumors

Title: Ph3 CAM2029 Lanreo ATG GEP-NET View

Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 CAM2029 Lanreo ATG GEP-NET View

Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 CAM2029 Lanreo ATG GEP-NET View

Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 CAM2029 Lanreo ATG GEP-NET View

Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 CAM2029 Lanreo ATG GEP-NET View

Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Denton

Phase: III

Osteosarcoma

Title: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Indication: Osteosarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Indication: Osteosarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Title: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Indication: Osteosarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II / III

Ovarian Cancer

Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Allen

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Denton

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano West

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Allen

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Denton

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST View

Description: A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)

Indication: Ovarian Cancer

Location: